A range of gene therapies are presently available in the medical tourism community of clinics outside the US and Europe, largely originating with a small number of companies such as BioViva Sciences and Triple Helix Science. These gene therapies tend to involve intramuscular (targeting muscle) or intranasal (targeting the brain) delivery of a modern adeno-associated virus (AAV) vector, such as AAV8 or AAV9.
A range of gene therapies are presently available in the medical tourism community of clinics outside the US and Europe, largely originating with a small number of companies such as BioViva Sciences and...
These gene therapies tend to involve intramuscular (targeting muscle) or intranasal (targeting the brain) delivery of a modern adeno-associated virus (AAV) vector, such as AAV8 or AAV9.
While AAV therapies have exhibited a concerning risk of life-threatening immune response when injected systemically at high doses, lower doses used in conjunction with local delivery appear to be relatively...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A range of gene therapies are presently available in the medical tourism community of clinics outside the US and Europe, largely originating with a small number of companies such as BioViva Sciences and Triple Helix Science. These gene therapies tend to involve intramuscular (targeting muscle) or intranasal (targeting the brain) delivery of a modern adeno-associated virus (AAV) vector, such as AAV8 or AAV9. While AAV therapies have exhibited a concerning risk of life-threatening immune response when injected systemically at high doses, lower doses used in conjunction with local delivery appear to be relatively safe.
Open the app view to save this story, compare related coverage, and continue from the same source.